Joseph Siletto
Growth Capital and Private Equity Investor
Needham, Massachusetts
Overview
Work Experience
Board Member
2024 - Current
Clinical stage biotech company focused on renal disease
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
Raised $266,000,000.00 from J.P. Morgan Asset Management, KB Investment, Japan Post Investment, Samsara BioCapital, TCG Crossover, DaVita Venture Group, Marshall Wace and Catalys Pacific.
Managing Partner
2024
Co-head of JP Morgan’s new growth investing effort in healthcare.
J.P. Morgan Ventures Energy Corporation provides commodity risk management solutions in both the physical .
Board Member
2021
Led $50 million growth equity investment into a founder-controlled neurovascular medical device company. Worked with founder to purchase a new 85,000 square foot manufacturing facility and negotiated a sale-leaseback transaction to generate a significant gain on the sale, sourced a first time credit facility and helped with the recruitment of the commercial team. Revenue grew 10x in 1st three years post investment. Employees grew from less than 100 to over 250.
Board Member
2021
Led minority equity investment in founder controlled business focused on infection prevention and staff safety
Interim Chief Executive Officer
2023 - 2024
Recapitalized existing portfolio company focused on infection prevention and surgical staff safety solutions. Restructured the company, turned the company profitable for the first time and created and implemented a new strategic plan focused on profitable growth.
Owner
1988
150+ acres of organic vineyards producing unique varietals
Managing Director
2017 - 2024
Leading healthcare-focused private capital firm with headquarters in Palo Alto, CA and offices in Shanghai and Beijing, China. Founded in 1996 with over US$6.5 Billion in assets under management. The firm invests across a wide range of sub segments of healthcare including but not limited to specialty pharmaceuticals, biotech, medical devices and services. Focus on commercial stage growth equity and controlling stake private equity investments. Source deals, negotiate and structure transactions and take active board roles on behalf of the firm.
Vivo is a global investment firm focused on healthcare with approximately $5.8 billion in AUM
Board Member
2021 - 2024
Interim Chief Executive Officer
2022 - 2022
Moved from board of directors to interim CEO role to oversee the transition from a founder run business in the tech-enabled digital pathology lab space. Managed the company, hired a recruiter and brought on an outside CEO and transitioned back to a board position.
HistoWiz provides automated histopathology for biomedical researchers.
Raised $36,765,000.00 from Vivo Capital, Asahi Kasei and venBio Partners.
Board Observer
2021 - 2024
Medical device manufacturer with an innovative robotic solution for dental implant procedures.
Board Member
2021 - 2024
Highly profitable pharma services company with a specialization in solving solubility issues for pharma and biotech customers.
Serán Bioscience is a contract development and manufacturing organization.
Raised $200,000,000.00 from Bain Capital Life Sciences and Vivo Capital.
Co-Founder/Angel Investor
2015 - 2024
Revenue stage, FDA-approved gynecology-focused medical device for minimally invasive removal of uterine polyps. Designed for both office-based and OR-based surgery with no capital equipment investment needed.